首页 | 官方网站   微博 | 高级检索  
     

基于网络药理学与分子对接技术对白术-半夏-茯苓配伍治疗胰腺癌作用机制的研究
引用本文:王吉荣,史小飞,种育晖,贾令茹,万雪莹,李睿旻.基于网络药理学与分子对接技术对白术-半夏-茯苓配伍治疗胰腺癌作用机制的研究[J].药学实践杂志,2023,41(10):616-624.
作者姓名:王吉荣  史小飞  种育晖  贾令茹  万雪莹  李睿旻
作者单位:海军军医大学药学系, 上海 200433;无锡联勤保障中心卫勤处, 江苏 无锡 214000;景洪市第一人民医院, 云南 西双版纳 666100
摘    要:目的 采用网络药理学和分子对接技术预测白术-半夏-茯苓配伍治疗胰腺癌的作用靶点,探讨其治疗胰腺癌的潜在分子作用机制。方法 通过中药系统药理学数据库和分析平台(TCMSP)、PharmMapper、OMIM、GeneCards、STRING、DAVID等在线数据库与Cytoscape软件构建一系列网络图、筛选核心靶点并对靶基因进行GO分析和KEGG通路富集分析,最后通过AutoDock软件对关键活性成分与潜在作用靶点进行分子对接验证。结果 共筛选得到药组活性成分35个,相关靶点190个,胰腺癌靶点1 566个以及白术-半夏-茯苓治疗胰腺癌的交集靶点76个。这些交集靶点主要参与基因表达的正调控,细胞因子介导的信号通路以及细胞凋亡调控等生物学过程,并与癌症通路、乙型肝炎、大肠癌、化学致癌受体激活、胰腺癌以及MAPK信号通路等相关。分子对接结果显示,白术-半夏-茯苓的主要活性成分与胰腺癌的潜在作用靶点间具有一定的结合活性。结论 白术-半夏-茯苓主要通过多成分、多靶点、多通路发挥对胰腺癌的治疗作用,为临床应用白术-半夏-茯苓配伍治疗胰腺癌提供一定的理论依据。

关 键 词:网络药理学  分子对接  白术-半夏-茯苓  胰腺癌
收稿时间:2023/6/12 0:00:00
修稿时间:2023/9/21 0:00:00

Research on the mechanism of Atractylodes-Pinellia-Poria in the treatment of pancreatic cancer based on network pharmacology and molecular docking
WANG Jirong,SHI Xiaofei,CHONG Yuhui,JIA Lingru,WAN Xueying,LI Ruimin.Research on the mechanism of Atractylodes-Pinellia-Poria in the treatment of pancreatic cancer based on network pharmacology and molecular docking[J].The Journal of Pharmaceutical Practice,2023,41(10):616-624.
Authors:WANG Jirong  SHI Xiaofei  CHONG Yuhui  JIA Lingru  WAN Xueying  LI Ruimin
Affiliation:Department of Pharmacy, Naval Medical University, Shanghai 200433, China;Department of Medical Health Service, Wuxi Joint Logistic Support Center, Wuxi 214000, China;Jinghong First People''s Hospital, Xishuang-banna 666100, China
Abstract:Objective To predict the target of Atractylodes-Panxia-Poria in the treatment of pancreatic cancer, and to explore its potential molecular mechanism by using network pharmacology and molecular docking. Methods Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), PharmMapper, OMIM, GeneCards, STRING, DAVID and Cytoscape software were used to construct a series of network diagrams. The core targets and conduct GO analysis and KEGG pathway enrichment analyses of the target genes were selected. Finally, molecular docking verification of key active ingredients and potential targets were conducted by AutoDock software. Results A total of 35 active ingredients, 190 related targets, 1566 targets of pancreatic cancer and 76 intersection targets were screened for the treatment of pancreatic cancer with Atractylodes-Panxia-Poria. These intersection targets were mainly involved in several biological processes, including positive regulation of gene expression, cytokine-mediated signaling pathway and regulation of apoptotic process, etc, which were also related to pathways in cancer, hepatitis B, colorectal cancer, chemical carcinogenesis-receptor activation, pancreatic cancer, and MAPK signaling pathway, etc. Molecular docking results showed that the main active components of Atractylodes-Panxia-Poria had certain affinity with the potential targets of pancreatic cancer. Conclusion Atractylodes-Panxia-Poria mainly exerts a therapeutic effect on pancreatic cancer through multi-component, multi-target and multi-pathway, which provides a certain theoretical basis for the clinical application of Atractylodes -Panxia-Poria in the treatment of pancreatic cancer.
Keywords:network pharmacology  molecular docking  Atractylodes-Pinellia-Poria  pancreatic cancer
点击此处可从《药学实践杂志》浏览原始摘要信息
点击此处可从《药学实践杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号